医疗保健利用率和左心室喷射分数分布在甲基胺使用中 相关心力衰竭 住院治疗
Veena Manja1, Alexander Tarlochan Singh Sandhu2, Steven Asch3
1Veterans Affairs, Northern California Health Care System, Mather, CA; University of California Davis, Sacramento, CA.
American heart journal
|March 16, 2024
概括
甲基胺使用相关心力衰竭 (MU-HF) 患者表现出较低的喷射率和更高的再入院率. 提高成治疗参与度对于这个不断增长的人口中获得更好的结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 成 药物 药物 药物 药物
- 公共卫生 公共卫生
背景情况:
- 甲基胺使用相关心力衰竭 (MU-HF) 是一个越来越严重的问题,有限的多中心数据.
- 现有研究在MU-HF定义中存在异质性,使临床理解复杂化.
研究的目的:
- 为了比较MU-HF和退伍军人的其他心力衰竭 (其他心力衰竭) 之间的左心室喷射分数 (LVEF) 分布.
- 评估MU-HF患者的甲基胺使用治疗开始后出院的情况.
- 评估MU-HF与其他HF的医疗保健利用模式.
主要方法:
- 一项观察性研究分析了从VA企业数据仓库获得的首次心力衰竭住院的退伍军人 (2007-2020年).
- 在住院1年内,MU-HF是使用ICD代码或毒理学识别的.
- 使用自然语言处理提取LVEF;通过记录追踪医疗保健利用率.
主要成果:
- 与其他HF患者相比,MU-HF患者的LVEF中位数较低 (30%vs. 40%).
- 违背医疗建议的出院率在MU-HF中更高 (8%与2%相比).
- 与其他HF相比,MU-HF的出院后治疗参与率较低 (30天后为18%),急诊次数和再住院次数较高.
结论:
- 显著的少数MU-HF患者存在保存的喷射分数 (HFpEF),影响分类和治疗.
- 较低的成治疗费用和高的非计划医疗保健利用率突出显示了迫切的需求.
- 优先考虑物质使用障碍治疗和护理协调是改善结果和减少医疗保健负担的关键.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:26Heart Failure Drugs: Inotropic Agents
584
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
584
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370